Company intelligence / Profile preview

Wuhan Recogen Biotechnology Co., Ltd.

Ownership: Private
Development stage: Phase 3

Overview

Wuhan Recogen Biotechnology was a joint venture founded in August 2021 between Jiangsu Recbio Technology Co., Ltd. and Shenzhen Rhegen Biotechnology Co. Ltd., focused on developing innovative mRNA vaccines using proprietary lyophilization technology to improve storage stability. Its lead program, R520A—an Omicron-targeted COVID‑19 mRNA vaccine—received clinical trial approval in the Philippines in June 2022. Preclinical studies showed strong neutralizing antibody responses against both Omicron and Delta variants[2][7]. However, as of late 2024, the company has been deregistered or dissolved as part of a restructuring by its parent company[6].

Therapeutic areas: Infectious Diseases
Modalities: mRNA vaccinesLyophilized (freeze-dried) mRNA-LNP formulations
Industry: Biotech

Drug pipeline

1 asset

R520A

Unknown

Partnerships

Shenzhen Rhegen Biotechnology Co. Ltd. (joint venture partner)

Beyond the preview

Go deeper on Wuhan Recogen Biotechnology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wuhan Recogen Biotechnology Co., Ltd..

Explore the full profile